|
Volumn 19, Issue 3, 2013, Pages 274-275
|
Metastasis awakening: The challenges of targeting minimal residual cancer
|
Author keywords
[No Author keywords available]
|
Indexed keywords
B RAF KINASE;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
GEFITINIB;
TRASTUZUMAB;
ARTICLE;
BREAST CANCER;
CELL PROLIFERATION;
COLORECTAL CANCER;
DISEASE FREE SURVIVAL;
DRUG EFFICACY;
GENE AMPLIFICATION;
HEAD AND NECK CANCER;
HUMAN;
LUNG CANCER;
LUNG NON SMALL CELL CANCER;
MELANOMA;
METASTASIS;
MOLECULARLY TARGETED THERAPY;
MUTATIONAL ANALYSIS;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
PROTEIN TARGETING;
RISK BENEFIT ANALYSIS;
ANTINEOPLASTIC AGENTS;
CHEMOTHERAPY, ADJUVANT;
DRUG RESISTANCE, NEOPLASM;
HUMANS;
MOLECULAR TARGETED THERAPY;
NEOPLASM METASTASIS;
NEOPLASM, RESIDUAL;
NEOPLASMS;
NEOPLASTIC CELLS, CIRCULATING;
TREATMENT OUTCOME;
|
EID: 84875183611
PISSN: 10788956
EISSN: 1546170X
Source Type: Journal
DOI: 10.1038/nm.3121 Document Type: Article |
Times cited : (57)
|
References (17)
|